FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382449206> ?p ?o ?g. }

• W4382449206 abstract "This analysis aimed to clarify the molecular basis of fragile X syndrome and explain the role of genetic material in the genetic disease's development and treatment. Fragile X syndrome is an X-linked mutation inheritance disorder. The mutated gene is called FMR-1. This is important for normal brain development and synaptic plasticity, which was verified and recognized in 1991, and this has become a hope for more clarification. FMR1 influences the translation of messenger RNA (mRNA), but identifying functional targets was complex and directly related to translational control and showed that dysregulated translation initiation signaling was observed for the FMR1 gene in the FMR1 knockout mouse model of FXS. Because of the epigenetic alteration, such as hypermethylated at the DNA promoter region, and chromatin modification, such as H3K9 methylation, the FMR1 gene can be imprinted. Still, their mechanisms of aberrant epigenetic marks play a role in the etiology of many neurodevelopmental disorders, some of which we still do not fully understand and need to show more. The opportunities for epigenetic markers to map and alter epigenetic marks and the potential for therapies based on epigenetics and noncoding manipulation. For neurodevelopmental and behavioral conditions, including mental retardation, autism, anxiety, and mood disturbance, FMR1 loss of control is a model. Most studies have focused on the new and effective approach for Fragile X syndrome, which is Gene therapy is unarguably the definitive way to treat and possibly cure genetic diseases. Many of them are under clinical trial, but more studies, such as the CRISPR/Cas9-based method, should be approved. Adeno-associated viral (AAV) vectors are highly effective for generating models. Most research is used in the mouse model of fragile X syndrome, where AAVs have been used to express fragile X mental retardation protein (FMRP), which is missing or highly reduced in the disorder. The vast expansions need southern blotting in myotonic dystrophy. Fragile X is diagnosed by a form of Southern blotting that relies on the size and the FRAXA gene's methylation status. Almost always, genetic testing is performed by PCR. The few Southern blotting uses include checking for significant destructive gene rearrangements and complete mutations of fragile X and myotonic dystrophy. Expansions suppress the expression of closely adjacent genes, causing loss of function. A named FMRI (fragile-X mental retardation syndrome) gene cDNA probe. Some unique molecular mechanisms, such as CGG expansion in Fragile-X syndrome, can make a particular sequence change in a gene far more probable than any other change." @default.
• W4382449206 created "2023-06-29" @default.
• W4382449206 creator A5067099468 @default.
• W4382449206 date "2023-01-01" @default.
• W4382449206 modified "2023-10-14" @default.
• W4382449206 title "The molecular basis of the Fragile X syndrome" @default.
• W4382449206 doi "https://doi.org/10.47743/jemb-2023-80" @default.
• W4382449206 hasPublicationYear "2023" @default.
• W4382449206 type Work @default.
• W4382449206 citedByCount "0" @default.
• W4382449206 crossrefType "journal-article" @default.
• W4382449206 hasAuthorship W4382449206A5067099468 @default.
• W4382449206 hasBestOaLocation W43824492061 @default.
• W4382449206 hasConcept C104317684 @default.
• W4382449206 hasConcept C118552586 @default.
• W4382449206 hasConcept C150194340 @default.
• W4382449206 hasConcept C169760540 @default.
• W4382449206 hasConcept C190727270 @default.
• W4382449206 hasConcept C205778803 @default.
• W4382449206 hasConcept C2777543196 @default.
• W4382449206 hasConcept C2777630245 @default.
• W4382449206 hasConcept C2779063550 @default.
• W4382449206 hasConcept C3020422209 @default.
• W4382449206 hasConcept C41091548 @default.
• W4382449206 hasConcept C54355233 @default.
• W4382449206 hasConcept C60644358 @default.
• W4382449206 hasConcept C71924100 @default.
• W4382449206 hasConcept C83640560 @default.
• W4382449206 hasConcept C86803240 @default.
• W4382449206 hasConceptScore W4382449206C104317684 @default.
• W4382449206 hasConceptScore W4382449206C118552586 @default.
• W4382449206 hasConceptScore W4382449206C150194340 @default.
• W4382449206 hasConceptScore W4382449206C169760540 @default.
• W4382449206 hasConceptScore W4382449206C190727270 @default.
• W4382449206 hasConceptScore W4382449206C205778803 @default.
• W4382449206 hasConceptScore W4382449206C2777543196 @default.
• W4382449206 hasConceptScore W4382449206C2777630245 @default.
• W4382449206 hasConceptScore W4382449206C2779063550 @default.
• W4382449206 hasConceptScore W4382449206C3020422209 @default.
• W4382449206 hasConceptScore W4382449206C41091548 @default.
• W4382449206 hasConceptScore W4382449206C54355233 @default.
• W4382449206 hasConceptScore W4382449206C60644358 @default.
• W4382449206 hasConceptScore W4382449206C71924100 @default.
• W4382449206 hasConceptScore W4382449206C83640560 @default.
• W4382449206 hasConceptScore W4382449206C86803240 @default.
• W4382449206 hasLocation W43824492061 @default.
• W4382449206 hasOpenAccess W4382449206 @default.
• W4382449206 hasPrimaryLocation W43824492061 @default.
• W4382449206 hasRelatedWork W2085216543 @default.
• W4382449206 hasRelatedWork W2097927344 @default.
• W4382449206 hasRelatedWork W2127142905 @default.
• W4382449206 hasRelatedWork W2347941509 @default.
• W4382449206 hasRelatedWork W2418188927 @default.
• W4382449206 hasRelatedWork W2439414065 @default.
• W4382449206 hasRelatedWork W3130501390 @default.
• W4382449206 hasRelatedWork W4382403705 @default.
• W4382449206 hasRelatedWork W4382449206 @default.
• W4382449206 hasRelatedWork W2187711227 @default.
• W4382449206 isParatext "false" @default.
• W4382449206 isRetracted "false" @default.
• W4382449206 workType "article" @default.